Landscape Capital Management L.L.C. Purchases 8,949 Shares of Guardant Health, Inc. $GH

Key Points

• Landscape Capital Management L.L.C. increased its stake in Guardant Health by 39.4%, owning 31,660 shares valued at approximately $1.35 million after acquiring an additional 8,949 shares in Q1.
• Several institutional investors, including SVB Wealth LLC and CWM LLC, have also made significant purchases or increases to their stakes in Guardant Health, indicating strong institutional interest.
• Guardant Health's shares have a recent average rating of "Buy," with analysts increasing target prices; for instance, Mizuho raised their target from $60 to $65.

Landscape Capital Management L.L.C. increased its holdings in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 39.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,660 shares of the company's stock after purchasing an additional 8,949 shares during the period. Landscape Capital Management L.L.C.'s holdings in Guardant Health were worth $1,349,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Janney Montgomery Scott LLC bought a new stake in Guardant Health in the 1st quarter valued at $232,000. Stifel Financial Corp boosted its stake in Guardant Health by 25.1% during the fourth quarter. Stifel Financial Corp now owns 49,927 shares of the company's stock valued at $1,525,000 after buying an additional 10,006 shares during the last quarter. Teacher Retirement System of Texas bought a new stake in Guardant Health in the first quarter worth $866,000. Fifth Third Bancorp purchased a new stake in shares of Guardant Health during the 1st quarter valued at about $279,000. Finally, Oppenheimer & Co. Inc. bought a new position in shares of Guardant Health in the 1st quarter valued at about $442,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on GH. Raymond James Financial upped their price objective on Guardant Health from $59.00 to $61.00 and gave the company an "outperform" rating in a research report on Thursday, July 31st. Mizuho raised their target price on shares of Guardant Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a report on Friday, June 13th. Evercore ISI raised shares of Guardant Health to a "strong-buy" rating in a research note on Monday, July 14th. Piper Sandler reissued an "overweight" rating and issued a $60.00 price objective (up from $50.00) on shares of Guardant Health in a research report on Tuesday, May 6th. Finally, Scotiabank raised their price objective on shares of Guardant Health from $57.00 to $60.00 and gave the stock a "sector outperform" rating in a research note on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating and sixteen have issued a Buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $57.50.

Guardant Health Stock Up 4.6%

NASDAQ:GH traded up $2.95 during midday trading on Monday, hitting $67.42. The stock had a trading volume of 2,864,324 shares, compared to its average volume of 2,800,602. The stock has a 50-day moving average of $52.07 and a 200 day moving average of $46.76. The company has a market capitalization of $8.41 billion, a price-to-earnings ratio of -20.13 and a beta of 1.45. Guardant Health, Inc. has a one year low of $20.14 and a one year high of $67.51.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.52) by $0.08. The firm had revenue of $232.09 million for the quarter, compared to the consensus estimate of $211.19 million. Guardant Health's quarterly revenue was up 31.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.84) EPS. Guardant Health has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Myrtle S. Potter sold 2,626 shares of the company's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $49.70, for a total value of $130,512.20. Following the completion of the sale, the director owned 18,180 shares of the company's stock, valued at approximately $903,546. This represents a 12.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Amirali Talasaz sold 100,000 shares of Guardant Health stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $50.88, for a total transaction of $5,088,000.00. Following the transaction, the chief executive officer directly owned 1,971,830 shares in the company, valued at approximately $100,326,710.40. The trade was a 4.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 235,442 shares of company stock worth $11,848,325. 6.10% of the stock is owned by corporate insiders.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.